RPGR 유전자의 변이와 관련된 X-연관 색소성 망막염 치료를 위한 유전자 치료 시험
RPGR 유전자의 변이와 관련된 X-연관 색소성 망막염 치료를 위한 AAV5-RPGR의 3상 무작위 통제 연구
A clinical trial of AAV5-RPGR vector for participants with X-linked retinitis pigmentosa (XLRP)
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (실제)
등록
단계
단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Amsterdam, 네덜란드, 1105AZ
- VUMC Amsterdam
-
Nijmegen, 네덜란드, 6525EX
- Radboudumc
-
-
-
-
-
Glostrup Municipality, 덴마크, 2600
- Rigshospitalet Glostrup
-
-
-
-
California
-
La Jolla, California, 미국, 92093 0946
- Shiley Eye Institute Jacobs Retina Center
-
Los Angeles, California, 미국, 90027
- Childrens Hospital
-
Palo Alto, California, 미국, 94303
- Stanford Health Care
-
-
Florida
-
Gainesville, Florida, 미국, 32607
- VitreoRetinal Associates, PA
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- Emory University
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02114
- Massachusetts General Hospital - Center for Celiac Research and Treatment
-
-
Michigan
-
Ann Arbor, Michigan, 미국, 48105
- Univ of Michigan Medical Center
-
-
North Carolina
-
Durham, North Carolina, 미국, 27705
- Duke Eye Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, 미국, 15213
- University of Pittsburgh Medical Center (UPMC)
-
-
Texas
-
Bellaire, Texas, 미국, 77401
- Retina Consultants of Houston
-
-
-
-
-
Ghent, 벨기에, 9000
- UZ Gent
-
-
-
-
-
Basel, 스위스, 4031
- University Hospital Basel, Eye Clinic/Institute of Molecular and Clinical
-
Lausanne, 스위스, 1004
- Universite de Lausanne, Hopital ophtalmique Jules-Gonin
-
-
-
-
-
Madrid, 스페인, 28040
- Hosp Univ Fund Jimenez Diaz
-
-
-
-
-
Edinburgh, 영국, EH3 9HA
- NHS Lothian
-
Glasgow, 영국, G12 0YN
- Gartnavel General Hospital
-
Leeds, 영국, LS9 7TF
- St James University Hospital
-
London, 영국, EC1V 2PD
- Moorfields Eye Hospital
-
-
-
-
-
Jerusalem, 이스라엘, 91120
- Hadassah Medical Center
-
-
-
-
-
Florence, 이탈리아, 50134
- Azienda Ospedaliero Universitaria Careggi
-
Milan, 이탈리아, 20142
- Ospedale San Paolo
-
Naples, 이탈리아, 80131
- Azienda Ospedaliera Univ.- Università Degli studi della Campania - Luigi Vanvitelli
-
Roma, 이탈리아, 00198
- IRCCS Fondazione G.B. Bietti per lo Studio e la Ricerca in Oftalmologia ONLUS
-
-
-
-
Ontario
-
Toronto, Ontario, 캐나다, M5G 1X8
- Hospital For Sick Children
-
-
-
-
-
Paris, 프랑스, 75012
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female
- 3 years of age or older
- Has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory
Exclusion Criteria:
- Has had ocular surgery within 3 months prior to screening or is anticipated to require ocular surgery within 6 months after the study intervention administration
- Any investigational ocular treatment or any other ocular treatment that could confound the interpretation of the efficacy results or affect participant compliance with the visit schedule
- Has undergone prior retinal surgery involving the macula, macular laser photocoagulation, external-beam radiation therapy, transpupillary thermotherapy, glaucoma filtration surgery or corneal surgery
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 하나의
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Experimental - Immediate Treatment
Intermediate dose. |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
다른 이름들:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
|
다른: Deferred Treatment
Deferred Treatment |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
다른 이름들:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
|
실험적: Experimental Immediate Treatment
Low dose. |
Bilateral, sub-retinal administration of AAV5-hRKp.RPGR - immediate treatment group
다른 이름들:
No intervention - deferred treatment group (Bilateral, sub-retinal administration of AAV5-hRKp.RPGR to be administered in the follow-up study) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline to Week 52 in Vision-guided Mobility Assessment (VMA) as Measured by the Ability of the Participant to Navigate Through a VMA Maze
기간: From Baseline to 52 Weeks
|
Change from baseline to Week 52 in VMA as measured by the ability of the participant to navigate through a VMA maze. |
From Baseline to 52 Weeks
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change From Baseline in Mean Retinal Sensitivity Within the Central 10 Degrees Excluding Scotoma (Mean Retinal Sensitivity Within the Central 10 Degree Excluding Scotoma in Static Perimetry [MRS10]) in Static Perimetry at Week 52
기간: From Baseline to Week 52
|
Change from baseline in mean retinal sensitivity within the central 10 degrees excluding scotoma (MRS10) in static perimetry at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change From Baseline in Mean Retinal Sensitivity of Worse-seeing Eye Within the Central 10 Degrees Excluding Scotoma in Static Perimetry (MRS10) at Week 52
기간: From Baseline to Week 52
|
Change from baseline in mean retinal sensitivity of worse-seeing eye within the central 10 degrees excluding scotoma in static perimetry (MRS10) at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Full Visual Field at Week 52
기간: From Baseline to Week 52
|
Pointwise response in full visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in Full Visual Field at Week 52
기간: From Baseline to Week 52
|
Pointwise response in worse-seeing eye in full visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in the Central 30 Degrees Visual Field at Week 52
기간: From Baseline to Week 52
|
Pointwise response in the central 30 degrees visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Retinal Function as Assessed by Pointwise Response in Worse-seeing Eye in the Central 30 Degrees Visual Field at Week 52
기간: From Baseline to Week 52
|
Pointwise response in worse-seeing eye in the central 30 degrees visual field at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change From Baseline in Retinal Function as Assessed by Mean Retinal Sensitivity Within the Full Visual Field (MRS90) in Static Perimetry at Week 52
기간: From Baseline to Week 52
|
Change from baseline in retinal function as assessed by mean retinal sensitivity within the full visual field (MRS90) in static perimetry at Week 52 will be assessed. |
From Baseline to Week 52
|
|
Change in Functional Vision by Using Vision-guided Mobility Assessment (VMA) Response in the "Worse-seeing Eye" at Week 52
기간: From Baseline to Week 52
|
Change in functional vision by using VMA assessment in the "Worse-seeing Eye" at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52
기간: From Baseline to Week 52
|
Change From Baseline in the Modified Low Luminance Questionnaire (mLLQ) Extreme Lighting Domain score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by Monocular Low Luminance Visual Acuity Using the Early Treatment Diabetic Retinopathy Study (ETDRS) Chart Letter score at Week 52
기간: From Baseline to Week 52
|
Change from baseline in visual function as assessed by monocular low luminance visual acuity using the ETDRS chart letter score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by monocular Best Corrected Visual Acuity (BCVA) Using the ETDRS Chart Letter Score at Week 52
기간: From Baseline to Week 52
|
Change From Baseline in visual function as assessed by monocular BCVA using the ETDRS chart letter score at Week 52. |
From Baseline to Week 52
|
|
Change From Baseline in Visual Function as Assessed by Low Luminance Visual Acuity Using the ETDRS Chart Letter Score in Worse-seeing Eye at Week 52
기간: From Baseline to Week 52
|
Change from baseline in visual function as assessed by low luminance visual acuity using the ETDRS chart letter score in worse-seeing eye at Week 52. |
From Baseline to Week 52
|
|
Number of Participants with Ocular and Non-ocular Adverse Events
기간: Day 1 - Week 52
|
Number of participants with ocular and non-ocular adverse events will be assessed. |
Day 1 - Week 52
|
|
Number of Participants With Abnormalities in Laboratory Assessments
기간: Day 1 - 52 Weeks
|
Number of participants with abnormalities in laboratory assessments will be assessed. |
Day 1 - 52 Weeks
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Study Director, MeiraGTx Ocular UK Ltd
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (실제)
기본 완료
연구 완료 (실제)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CR109258
- 2020-002873-88 (EudraCT 번호)
- MGT-RPGR-021 (기타 식별자: MeiraGTx Ocular UK Ltd)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .